The demographics of people hospitalized for hemolytic uremic syndrome (HUS) in the U.S. have shifted over the last decade, with…
Articles by Marisa Wexler, MS
Soliris (eculizumab) can safely be discontinued in children with atypical hemolytic uremic syndrome (aHUS) whose disease is in…
Soliris (eculizumab), an approved treatment for atypical hemolytic uremic syndrome (aHUS), is now available to patients in China,…
When treating atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab), the medication can be safely discontinued after the…
Sirnaomics has launched preclinical testing of a first candidate therapy developed with its GalAhead platform for complement-mediated diseases, including…
Eight cases of atypical hemolytic uremic syndrome (aHUS) that occurred in people with underlying conditions that could have prompted…
The case of a woman who developed atypical hemolytic uremic syndrome (aHUS) during pregnancy was described in a recent…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
Five children in India who developed or had a relapse of atypical hemolytic uremic syndrome (aHUS) in the summer…
Ultomiris (ravulizumab) was reportedly used for the first time to control atypical hemolytic uremic syndrome (aHUS) in a…